Latest Innovation News

NeuRizer Ltd has completed a $150,000 private share placement, issuing 100 million new shares to support its NeuRizer Urea Project and general working capital needs.

Archer Materials has been granted a pivotal US patent for its Biochip technology, safeguarding its intellectual property and positioning the company for strategic entry into the lucrative US medical diagnostics market.

Emyria Limited announces key leadership shifts with Greg Hutchinson stepping up as Executive Chairman and Dr. Michael Winlo transitioning to Chief Scientific Officer, aiming to scale innovative mental health therapies amid growing demand.

Nanoveu has completed due diligence and is set to finalise its acquisition of EMASS, integrating cutting-edge AI-enabled SoC technology into its EyeFly3D™ platform to expand applications across wearables, IoT, and smart devices.

Mighty Kingdom Ltd has appointed Dylan Miklashek as Interim CEO and Duncan Gordon as Non-Executive Chair, signaling a fresh leadership approach amid a company restructuring.

Compumedics has locked in a pivotal five-year contract with Philips Australia, cementing Somfit as the leading device for pharmacy-based sleep testing and underpinning significant SaaS revenue growth through 2028.

Amcor plc has entered a definitive agreement to acquire Berry Global Group in a $9.9 billion all-stock transaction, aiming to create a global packaging leader. The merger, pending shareholder and regulatory approvals, is expected to close mid-2025.

The GPT Group has forged a strategic partnership for Rouse Hill Town Centre and increased its ownership in Highpoint Shopping Centre to 25%, unlocking $176 million in net proceeds to reduce gearing and fuel future investments.

TechGen Metals has identified significant bedrock conductors and magnetic features at its Blue Devil Project in Western Australia through its maiden airborne electromagnetic survey, spotlighting promising copper and gold exploration targets.

LTR Pharma has inked a national distribution agreement with Symbion, positioning its innovative ED treatment SPONTAN® for broad pharmacy access across Australia ahead of its commercial launch.

Chrysos Corporation reports a robust Q2 FY25 with a 12% quarter-on-quarter and 53% year-on-year revenue increase, driven by expanding international sales and rising sample volumes. The company secured two new contracts, boosting its PhotonAssay™ footprint and maintaining strong financial health.

Zoono Group reports expanding global trials of its shelf-life extension technology, engaging over 40 supermarket and packaging companies, while refining its product and managing cash flow amid cautious commercial adoption.